ScreenerHero

HRMYHarmony Biosciences Holdings, Inc.

NAS · US · Healthcare · Biotechnology · harmonybiosciences.com
38.15USD-4.46%Mkt Cap: 2.22B $P/E: 12.35

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAK…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.22B $
Enterprise Value1.71B $
Revenue (TTM)959.90M $
Gross Profit670.11M $
Net Income (TTM)158.69M $
Revenue/Share16.63 USD
Last Price38.15 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees293
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)12.35
P/E (Forward)5.69
PEG—
EV/EBITDA6.68
EV/Revenue1.78
P/S2.31
P/B2.21
EPS (TTM)2.94
EPS (Forward)6.69
52W Range
25.5282% of range40.87
52W High40.87 USD
52W Low25.52 USD
Profitability
Gross Margin77.16%
Oper. Margin34.18%
EBITDA Margin26.67%
Profit Margin18.27%
ROE18.24%
ROA12.48%
Growth
Revenue Growth30.30%
Earnings Growth88.20%
Cash Flow & Leverage
Operating CF348.20M $
CapEx (TTM)310.00K $
FCF Margin19.05%
FCF Yield8.23%
Net Debt-507.60M $
Net Debt/EBITDA-1.98
Balance Sheet
Debt/Equity0.19
Current Ratio3.48
Quick Ratio3.33
Book Value/Sh17.19 USD
Cash/Share11.47 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.1 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)46.10 USD
Upside (mean)+20.8%
Target Range30.00 USD – 70.00 USD
$30.00+20.8% to mean$70.00
# Analysts10
Ownership
Shares Out.58.24M
Float52.08M
Insiders11.63%
Institutions99.62%
Short Interest
Short Ratio5.3d
Short % Float10.31%
Short % Out.7.72%
Shares Short4.50M
Short (prev mo.)4.61M
Technical
SMA 5036.25 (+5.2%)
SMA 20033.79 (+12.9%)
Beta0.91
S&P 52W Chg18.16%
Avg Vol (30d)808.09K
Avg Vol (10d)644.09K
Technical Indicators
RSI (14)53.9
MACD0.9618
MACD Signal0.9655
MACD Hist.-0.0036
BB Upper40.82 USD
BB Middle37.54 USD
BB Lower34.26 USD
BB Width17.48%
ATR (14)1.414 USD
Vol Ratio (20d)0.47x